http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_57df8ccd327ab392aced50ec01d6a668
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Anderson Kenneth C. Anderson |
| name | Kenneth C. Anderson Kenneth C Anderson Kenneth. C Anderson |
| given-name | Kenneth. C Kenneth C Kenneth C. |
| organization-name | 2Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; American Society of Clinical Oncology, Alexandria, VA; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Authors' Affiliations: 1Massachusetts General Hospital Cancer Center, 2Dana-Farber Cancer Institute, and 3Beth Israel Deaconess Medical Center, Boston, MA, Harvard Medical School, Boston, Massachusetts Dana Farber Cancer Institute Harvard Medical School Boston MA USA From the Bing Program for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston; CareStat, Newton, MA; UCLA Medical Center, Los Angeles, CA; Greenebaum Cancer Center, University of Maryland, Baltimore, MD; Nevada Cancer Center, Las Vegas, NV; Fred Hutchinson Cancer Research Center, Seattle WA; and Karolinska University Hospital, Stockholm, Sweden Department of Medicine, Harvard Medical School, Boston, MA;; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; and Medical Oncology, and; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA; Authors' Affiliations: 1Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, T. Campanella Cancer Center, Salvatore Venuta University Campus; 2Pathology Unit, Magna Graecia University, Catanzaro, Italy; 3Department of Medical Sciences University of Milan, Hematology 1, IRCCS Policlinico Foundation, Milan, Italy; 4Department of Experimental and Diagnostic Medicine, Interdepartmental Center for Cancer Research, University of Ferrara, Ferrara, Italy; 5Division of Medical Oncology C, Istituto Nazionale per la Ricerca sul Cancro and Department of Internal Medicine, University of Genoa, Genoa, Italy; 6Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy; 7Department of Medical Oncology, Dana-Farber Cancer Institute; 8Boston Veterans Administration Healthcare System, West Roxbury, Boston, Massachusetts; and 9Temple University's College of Science & Technology, Philadelphia, Pennsylvania *Department of Medical Oncology, The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; From the Divisions of Hematologic Malignancies and Cancer Pharmacology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02215. Department of Hematologic Oncology Dana‐Farber Cancer Institute Boston Massachusetts Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115-6017; Department of Medicine, Harvard Medical School, Boston, MA 02115; and Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 Andrzej J. Jakubowiak, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Andrzej J. Jakubowiak, Don M. Benson, Paul G. Richardson, and Kenneth C. Anderson, Multiple Myeloma Research Consortium, Norwalk, CT; Don M. Benson, The Ohio State University Comprehensive Cancer Center, Columbus, OH; William Bensinger, Fred Hutchinson Cancer Research Center, Seattle, WA; David S.D. Siegel, Hackensack University Medical Center, Hackensack, NJ; Todd M. Zimmerman, University of Chicago Medical Center,... 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana‐Farber Cancer Institute Harvard Medical School Boston Massachusetts USA From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA;; Department of Medicine, Harvard Medical School, Boston, MA; 2Harvard Medical School, Boston, MA;; 4Dana-Farber Cancer Institute, Boston, MA; and Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 1Department of Medical Oncology,; 2Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, From the Department of Adult Oncology, Dana Farber Cancer Institute; and Department of Medicine, Harvard Medical School, Boston, MA; Bayer Diagnostics, Walpole, MA; Academic Hospital, Vrije Universiteit, Amsterdam, The Netherlands; and Department of Medical Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada. From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Salmedix, Inc, San Diego, CA; and the First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan. From the Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN; and the Division of Hematologic Malignancies, Dana-Farber Cancer Institute and the Department of Medicine, Harvard Medical School, Boston, MA. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Harvard Medical School Boston MA USA; Medical Oncology Dana‐Farber Cancer Institute Boston MA USA Harvard Medical School, Boston, MA; and; Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, MA Authors' Affiliation: Dana-Farber Cancer Institute 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. From the Department of Medical Oncology and the Department of Biostatistics, Dana-Farber Cancer Institute; and the Department of Medicine, Harvard Medical School, Boston, MA. Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA 1Bing Center for Waldenström's Macroglobulinemia, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts; 5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; 15Department of Medicine, Harvard Medical School, Boston, Massachusetts. Department of Medical Oncology Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA; Jerome Lipper Multiple Myeloma Center Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 2Dana-Farber Cancer Institute, Boston, Massachusetts. 1Jerome Lipper Multiple Myeloma Center, Medical Oncology, and From the Departments of Medical Oncology and Biostatistics, Dana-Farber Cancer Institute; the University of Leeds, West Yorkshire, United Kingdom; and the Department of Medicine, Brigham and Woman's Hospital, Harvard Medical School, Boston, MA. From the Department of Adult Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and the Department of Medicine, Harvard Medical School, Boston, MA. 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Professor of Medicine, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology Dana Farber Cancer Institute, Harvard Medical School Boston Massachusetts Authors' Affiliations: 1Medical Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University and T. Campanella Cancer Center, Catanzaro; 2Department of Medical Sciences University of Milan, Hematology 1, IRCCS Policlinico Foundation, Milan; 3Human Pathology and Oncology Department, University of Siena, Siena, Italy; 4Department of Medical Oncology, Dana-Farber Cancer Institute; 5Boston Veterans Administration Healthcare System, West Roxbury, Boston, Massachusetts; and 6Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania Department of Medical Oncology Dana‐Farber Cancer Institute Boston MA USA; Department of Medicine Harvard Medical School Boston MA USA Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; 6Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana–Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. From the Winship Cancer Institute, Emory University, Atlanta, GA; Dana Farber Cancer Institute, Boston, MA; St Vincent's Comprehensive Cancer Center, New York, NY; University of North Carolina at Chapel Hill; Myeloma and Transplant Research Center, Arkansas Cancer Research Center, Little Rock; Institute for Myeloma and Bone Cancer Research, West Hollywood, CA; Northwestern University, Chicago, IL; and Millennium Pharmaceuticals, Cambridge, MA. From the Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; St Vincent's Comprehensive Cancer Center, New York, NY; the Mayo Clinic, Rochester, MN; H. Lee Moffitt Cancer Center, Tampa, FL; and Celgene, Summit, NJ. Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA University of Torino, Torino, Italy. From the Division of Hematologic Malignancies, Dana-Farber Cancer Institute, the Department of Medicine, Brigham and Womens Hospital, and Department of Pathology, Harvard Medical School, Boston, MA; SyStemix Inc, Palo Alto, CA; the Division of Laboratories, School of Veterinary Medicine, Tufts University, Boston, MA; and the Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan. Jesús F. San-Miguel and María Victoria Mateos, Servicio e Hematologia, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Institut de Bilogia Molecular de Barcelona (Universidad de Salamanca–Spanish National Research Council), Salamanca; Joan Bladé, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; David Siegel, Hackensack... From the Center for Hematologic Oncology and Department of Biostatistics, Dana-Farber Cancer Institute; Department of Medicine, Brigham and Women's Hospital; and Harvard Medical School; all of Boston, MA. From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; the 1st Department of Internal Medicine, Fukuoka University, Nanakuma Jonan Fukuoka, Japan; and the Department of Dermatology, Emory University School of Medicine, Atlanta, GA. Authors' Affiliations: 1Division of Hematologic Neoplasia, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; 2Departments of Cancer Biology and Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, VA Boston Healthcare System and Harvard Medical School, Boston, MA; the Division of Hematology, Mayo Clinic, Rochester, MN; and Celgene Corporation, Warren, NJ. 1Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; 2Blood Cancer Research Partnership (BCRP), Boston, Massachusetts. The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA Department of Medicine Harvard Medical School Boston Massachusetts USA; Department of Medical Oncology, Dana Farber Cancer Institute Jerome Lipper Multiple Myeloma Center Boston Massachusetts USA 4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA Department of Medical Oncology Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115 Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA Department of Medical Oncology and; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Harvard Medical School, Boston, MA, USA; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; From the Departments of Anatomy and Surgery and the J.G. Brown Regional Cancer Center, University of Louisville, Louisville, Kentucky From The Jerome Lipper Multiple Myeloma Center, the Department of Medical Oncology, Cancer Biology, Boston Veteran Affairs Healthcare System and Biostatistical Sciences, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA. 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Jerome Lipper Myeloma Center, Division of Hematologic Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts. From the Department of Medical Oncology, Dana-Farber Cancer Institute; and Beth Israel Deaconess Medical Center, Boston; and Millennium Pharmaceuticals, Cambridge, MA; St Vincent's Comprehensive Cancer Center, New York, NY; H. Lee Moffitt Cancer Center, Tampa, FL; and Celgene, Summit, NJ. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, 44 Binney Street, Boston, MA 02115, USA ; ; From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA. From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Celgene, Warren, NJ. 6Dana-Farber Cancer Institute, Boston, MA; From the Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Authors' Affiliation: Dana-Farber Cancer Institute, Boston, Massachusetts The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;; Department of Medicine, Harvard Medical School, Boston, MA; From the L'Institut National de la Santé et de la Recherche Médicale U892, Université de Nantes, Institut Régional du Cancer Nantes-Atlantique; Centre Hospitalier Universitaire de Nantes, Institut Régional du Cancer Nantes-Atlantique, Laboratoire d'Hématologie; Centre Hospitalier Universitaire de Nantes, Institut Régional du Cancer Nantes-Atlantique, Service d'Hématologie Clinique, Nantes; Centre de Lutte contre le Cancer Nantes-Atlantique, Institut Régional du Cancer Nantes-Atlantique, Nantes-Saint... †LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;; ‡Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; 3Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts. From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Department of Experimental Haematology, The Royal London School of Medicine, London, United Kingdom. Medical Oncology, Dana-Farber Cancer Institute and Authors' Affiliations: 1Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute; 2VA Boston Healthcare System, Harvard Medical School, Boston, Massachusetts; 3Centre Hospitalier Universitaire de Nantes, IRCNA, Laboratoire d';Hématologie, Nantes, France; and 4University of “Magna Græcia,” Catanzaro, Italy 1The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School and Antonio Palumbo, Stefania Oliva, Simona Caltagirone, Sara Bringhen, and Francesca Gay, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute della Salute e della Scienza di Torino; Roberto Passera, University of Torino, Torino; Massimo Offidani, Clinica di Ematologia, AUO Ospedali Riuniti di Ancona, Ancona; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico, Referral Cancer Center of Basilicata, Rionero in Vulture; Maria T. Petrucci, Sapienza University of Rome,... abcFrom the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, and Harvard Medical School; Harvard Medical School, Dana-Farber Cancer Institute, and Brigham and Women's Hospital; and Jerome Lipper Multiple Myeloma Center, Kraft Family Donor Center, and Harvard Medical School, Boston, Massachusetts. Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and 2Dana-Farber Cancer Institute,; 3Harvard Medical School, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Authors' Affiliations: 1Hospital Universitario de Salamanca, Salamanca, Spain; 2Hospital Clínico y Provincial de Barcelona, Barcelona, Spain; 3Dana-Farber Cancer Institute, Boston Massachusetts; 4Clínica Universitaria de Navarra, Pamplona, Spain; 5Hospital Germans Trias i Pujol, Badalona, Spain; 6Hospital Universitario La Fe, Valencia, Spain; and 7Hospital Universitario 12 de Octubre, and 8Pharma Mar, Colmenar Viejo, Madrid, Spain Medical Oncology, Dana‐Farber Cancer Institute Harvard Medical School Boston Massachusetts 3Dana Farber Cancer Institute, Boston, Massachusetts. From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston MA; Department of Medicine, Harvard Medical School, Boston, MA; Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA; Beth Israel Deaconess Medical Center (BIDMC) Genomics Center, BIDMC, Harvard Institutes of Medicine, Boston, MA; Boston VA Health Care System, Boston, MA. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 1Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts and The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusettes From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Chemistry, Dartmouth College, Hanover, NH; and Department of Pharmacology, Dartmouth Medical School, Hanover, NH. 3Dana-Farber Cancer Institute, Boston, Massachusetts 2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana–Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115; Broad Institute of Harvard University and Massachusetts Institute of Technology, 320 Charles Street, Cambridge, MA 02141; and Howard Hughes Medical Institute, Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, MA 02138 From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Boston Veterans Administration (VA) Healthcare System, Harvard Medical School, Boston, MA. 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute;; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts; Authors' Affiliations: 1Zalicus Inc., Cambridge, Massachusetts; 2The Institute for Drug Development, CTRC, University of Texas Health Science Center, San Antonio, Texas; and 3Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts J. Lipper Cancer Center for Multiple Myeloma, Dana-Farber Cancer Institute, Harvard University, Boston, MA; Authors' Affiliations: 1Dana-Farber Cancer Institute; 2VA Boston Healthcare System; and 3Harvard Medical School, Boston, Massachusetts; Authors' Affiliations: 1Dana-Farber Cancer Institute; 2VA Boston Healthcare System; and 3Harvard Medical School, Boston, Massachusetts 1Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2Harvard Medical School, Boston, MA Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School Jerome Lipper Multiple Myeloma Center Dana‐Farber Cancer Institute Boston MA USA From the Servicio de Hematología, Hospital Universitario de Salamanca (Centro de Investigación del Cáncer–Instituto de Biología Molecular del Centro del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas) Salamanca, Spain; University Hospital Nantes, Nantes, France; Institute of Hematology, Royal Prince Alfred Hospital, Sidney, Australia; and the Dana-Farber Cancer Institute, Boston, MA The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and From Medizinische Klinik, Klinikum Innenstadt, and Genzentrum, Universität München, München, Germany; Cornell University Medical College, New York, NY; and Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA. Authors' Affiliations: 1Jerome Lipper Multiple Myeloma Center, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; 3Profectus BioSciences Inc.; 4rel∼MD, Inc., Baltimore, Maryland; and 5Research Institute and Hospital, National Cancer Center, Korea; Authors' Affiliations: 1Jerome Lipper Multiple Myeloma Center, 2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; 3Profectus BioSciences Inc.; 4rel∼MD, Inc., Baltimore, Maryland; and 5Research Institute and Hospital, National Cancer Center, Korea 3Jerome Lipper Multiple Myeloma Center; Dana-Farber Cancer Institute, Boston, Massachusetts; and Department of Medicine Harvard Medical School Boston MA USA; Lipper Center for Multiple Myeloma Dana Farber Cancer Institute Boston MA USA *Dana-Farber Cancer Institute and The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Myeloma Research, Department of Medical Oncology, Dana-Farber Cancer Institute, and 2Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;; 6Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; and 1Department of Medical Oncology and; 2Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School; Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China Dana-Farber Cancer Institute Boston, Massachusetts LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and From the Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School; the Department of Medicine, Harvard Medical School; and the Retina Research Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center and From the Dana-Farber Cancer Institute, Boston, MA; University of Arkansas for Medical Sciences, Little Rock, AR; Cedars-Sinai Medical Center, Los Angeles, CA; Northwestern Memorial Hospital, Chicago, IL; St Vincent's Comprehensive Cancer Center, New York, NY; Alta Bates Cancer Center, Berkeley, CA; Mayo Clinic, Rochester, MN; and Millenium Pharmaceuticals, Inc., Cambridge, MA. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Antonio Palumbo and Alessandra Larocca, University of Torino, Torino; Michele Cavo, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Jesus F. San Miguel, University Hospital of Salamanca, Salamanca, Spain; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Gareth Morgan, Royal Marsden Hospital, London, United Kingdom; Ola Landgren, National Cancer Institute, Bethesda, MD; Roman Hajek, University of... Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School, Boston, Massachusetts; 13Jerome Lipper Multiple Myeloma Center, Dana–Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Department of Adult Oncology, Harvard Medical School, Boston, Massachusetts 02115, USA. The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and 1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, 44 Binney Street, Dana 1B02, Boston, Massachusetts 02115, United States Dana-Farber Cancer Institute 3 Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, , Boston, Massachusetts 02215, USA Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;; Department of Medicine, Harvard Medical School, Boston, MA; 2Dana-Farber Cancer Institute, Boston, Massachusetts Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA. Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; Authors' Affiliations: 1Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center; 2Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 3Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and 4Astex Therapeutics Ltd, Cambridge, United Kingdom Department of Medical Oncology, Dana–Farber Cancer Institute, Boston, MA 02115; Department of Medicine, Harvard Medical School, Boston MA; and; Jerome Lipper Center for Multiple Myeloma, Dana-Farber Cancer Institute, Boston, MA Jerome Lipper Multiple Myeloma Center and; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;; Department of Medicine, Harvard Medical School, Boston, MA; and From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and VA Boston Healthcare System, Harvard Medical School, Boston, MA; University of “Magna Græcia,” Catanzaro, Italy; ImmunoGen, Inc, Cambridge, MA; and Callisto Pharmaceuticals Inc, New York, NY. From the the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA; and Department of Medicine, Harvard Medical School, Boston, MA. From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA; and Boston VA Healthcare System, Department of Medicine, Harvard Medical School, Boston, MA. 5Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA Authors' Affiliations: 1Department of Internal Medicine V, 2Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center and Department of Internal Medicine V; 3National Center for Tumor Diseases, University of Heidelberg; 4Max-Eder Group Experimental Therapies for Hematologic Malignancies, German Cancer Research Center (DKFZ); 5Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; 6Department of Medical Oncology, Dana-Farber Cancer Institute; 7Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; 8Center for Nanomedicine and Theranostics & Department of Chemistry; and 9Center for Microbial Biotechnology, Department of Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark From the Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, and the Department of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and GlaxoSmithKline, Research Triangle Park, NC. From the Veterans Administration (VA) Boston Health Care System and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA. 3Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and Authors' Affiliations: 1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; 2Department of Oncology/Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm; and 3Oncopeptides AB, Karolinska Institutet Science Park, Solna, Sweden Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Division of Hematologic Malignancy, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 2Dana-Farber Cancer Institute, Boston, Massachusetts; and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215; Dana-Farber Cancer Institute Dana-Farber Cancer Institute, Boston, MA;; Department of Medical Oncology, Harvard Medical School, Boston, MA; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Authors' Affiliations: 1Functional Genomics of Cancer Unit, Division of Molecular Oncology, San Raffaele Scientific Institute, Milan, Italy; 2Jerome Lipper Center for Multiple Myeloma Research and LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA From the Dana-Farber Cancer Institute. From the Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Center, Buffalo, NY, University of Maryland, Baltimore, MD; and Rocky Mountain Cancer Center, Denver, CO. Dana-Farber Cancer Institute, Boston, MA;; Harvard Medical School, Boston, MA; 9Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 1Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Authors' Affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Dana‐Farber Cancer Institute Boston MA USA Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; 2Harvard Medical School, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, Massachusetts Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA Author's Affiliation: Dana-Farber Cancer Institute, Medical Oncology, Boston, Massachusetts Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115; Department of Medical Oncology, Dana-Farber Cancer Institute, and; Departments of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, MA Department of Medical Oncology Jerome Lipper Multiple Myeloma Center Dana Farber Cancer Institute Boston MA USA; Department of Medicine Harvard Medical School Boston MA USA Dana Farber Cancer Institute, Boston, Massachusetts, United States Charles A. Schiffer, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Meghan Delaney, Children’s National Medical System & George Washington University, Washington DC; Heather Hume, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada; Anthony J. Magdalinski, Alliance Cancer Specialists, Sellersville, PA; Jeffrey J. McCullough, University of Minnesota, Minneapolis, MN; James L. Omel,... From the Department of Adult Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA; and Celgene Corporation, Warren, NJ. Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215, USA Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA Harvard Medical School, Boston, MA;; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA Authors' Affiliations: 1Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute; 2Massachusetts General Hospital, and 3VA Boston Healthcare System, Boston, Massachusetts; 4Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; and 5National Institute for Cellular Biotechnology, Dublin City University and 6Department of Haematology, Mater Misericordiae University Hospital, Dublin, Ireland Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA From the Princess Margaret Hospital, Toronto, Ontario, Canada; West Los Angeles Veterans Affairs Medical Center/University of California at Los Angeles, and Southern California Kaiser Permanente Medical Group, Los Angeles; University of California at San Francisco, San Francisco, CA; University of South Florida, Miami, FL; Johns Hopkins University, Baltimore, MD; University of Texas at San Antonio, San Antonio, TX; University of Pennsylvania, Philadelphia, PA; University of Nebraska, Omaha, NE; Loyola... 2Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, USA Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana–Farber Cancer Institute, Boston, MA 02215; From the Roswell Park Cancer Institute, Buffalo; New York–Presbyterian Hospital, New York, NY; Alta Bates Cancer Center, Berkeley, CA; University of Pennsylvania Cancer Center, Philadelphia, PA; Emory University, Atlanta, GA; Millennium Pharmaceuticals Inc, Cambridge; Dana-Farber Cancer Institute, Boston, MA; University Hospital Rotterdam, Rotterdam, the Netherlands; Hospital Claude Huriez, Lille; Hotel Dieu Hospital, Nantes, France; Hadassah University Hospital, Jerusalem, Israel; Universitaetsklinikum... Authors' Affiliation: Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Myeloma Research, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center; Department of Medical Oncology; Dana-Farber Cancer Institute; Harvard Medical School; Boston MA USA Brigham & Women's Hospital, Boston, MA;; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Division of Hematologic Malignancy, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Department of Medicine, Harvard Medical School, Boston, MA. 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute Harvard Medical School; From the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom; Royal Prince Alfred Hospital, University of Sydney, Sydney, New South Wales, Australia; and Hospital Universitario de Salamanca, Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cancer (Universidad de Salamanca–Consejo Superior de Investigaciones Científicas), Salamanca, Spain. Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana–Farber Cancer Institute, Boston, MA 02115; Department of Medicine, Harvard Medical School, Boston, MA 02115; Massachusetts Eye and Ear Infirmary, Harvard Medical School, 234 Charles Street, Boston, MA 02114; BIDMC Genomics Center, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, Boston, MA 02115; Aton Pharma, Inc., Tarrytown, NY 10591; and Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New... Department of Medical Oncology, Dana‐Farber Cancer Institute Harvard Medical School Boston Massachusetts From the Divisions of Hematologic Malignancies and Neoplastic Disease Mechanisms, Dana-Farber Cancer Institute, Boston; the Department of Medicine, Harvard Medical School, Boston, MA; the Department of Haematology, Singapore General Hospital, Singapore; and Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA. 2Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts; and From Science Research Laboratory Inc, Somerville, MA; the Center for Regenerative Medicine and Technology, Massachusetts General Hospital; and the Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. From the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston; Millennium Pharmaceuticals Inc, Cambridge, MA; St Vincent’s Cancer Center; York Presbyterian Hospital, New York, NY; University of Arkansas, Little Rock, AR; Institute for Myeloma and Bone Cancer Research, West Hollywood; Alta Bates Cancer Center, Berkley, CA; Robert H. Lurie Cancer Center, Chicago, IL; Hackensack University Medical Center, Hackensack, NJ; New Sparrow Regional Cancer Center, Lansing, MI; M.D. Anderson Cancer... Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA From the Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA; the Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA; the Department of Haematology, Singapore General Hospital, Singapore; the Academisch Ziekenhuis, Vrije Universiteit, Amsterdam, The Netherlands; and the Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada. 1Dana-Farber Cancer Institute, 2Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute;; 3Harvard Medical School, Boston, Massachusetts; Authors' Affiliations: 1Dana-Farber Cancer Institute, 2Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; 3Community Hospital of Monterey Peninsula, Monterey, California; 4Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; and 5Keryx Biopharmaceuticals, Inc., New York, New York Authors' Affiliations: 1Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center; 2Bing Center for Waldenström's Macroglobulinemia; 3Department of Pediatric Oncology, Dana-Farber Cancer Institute; 4Department of Medicine, Harvard Medical School, Boston; and 5Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; Authors' Affiliations: 1Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center; 2Bing Center for Waldenström's Macroglobulinemia; 3Department of Pediatric Oncology, Dana-Farber Cancer Institute; 4Department of Medicine, Harvard Medical School, Boston; and 5Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts From the Dana-Farber Cancer Institute, Boston, MA; the Veteran's Administration (VA) Boston Healthcare System, Boston, MA; the Brigham and Woman's Hospital, Harvard Medical School, Boston, MA; and the University of Magna Græcia and Cancer Center, Catanzaro, Italy. Paul G. Richardson, Robert Schlossman, Irene M. Ghobrial, Nikhil Munshi, Jacob Laubach, Teru Hideshima, Kathleen Colson, and Kenneth C. Anderson, Dana-Farber Cancer Institute; Noopur Raje, Massachusetts General Cancer Center, Boston, MA; Jeff Wolf and Tom Martin, University of California San Francisco, San Francisco; David Irwin, Alta Bates Cancer Center, Berkeley; Amrita Krishnan, City of Hope, Duarte, CA; Andrzej Jakubowiak, University of Michigan, Ann Arbor; Jeff Zonder, Karmanos Cancer Center,... From Partners AIDS Research Center, Massachusetts General Hospital, Charlestown, and the Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; the Department of Epidemiology and Biostatistics, University of California, San Francisco; and the Departments of Microbiology and Medicine, Myles H. Thaler Center for AIDS Research, University of Virginia Health Systems, Charlottesville. abcdFrom Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, and Beth Israel Hospital, Boston, Massachusetts. Authors' Affiliations: 1Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute; 2Department of Pathology, Brigham and Women's Hospital; 3MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; 4Abraxis Bioscience LLC, Los Angeles, California; 5Keryx Biopharmaceuticals, Inc., New York, New York; and 6Cellworks Group, Inc., Saratoga, California From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and the Boston VA Healthcare System, Harvard Medical School, the Harvard School of Public Health, Boston, MA; the University of Leeds, United Kingdom; the Mayo Clinic Medical Center, Rochester, MN; and the Weil College of Cornell University, New York, NY. 1Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; 2Harvard Medical School, Boston, MA The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 2Multiple Myeloma Program, Dana-Farber/Harvard Cancer Center, Boston, MA Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA Authors' Affiliation: Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts Authors' Affiliations: 1Veterans Administration Boston Healthcare System, Boston; and 2Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center Dana‐Farber Cancer Institute Harvard Medical School Boston Massachusetts USA 2LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts. *Department of Medical Oncology and Cancer Vaccine Center, Dana–Farber Cancer Institute and Department of Medicine, and Department of Medical Oncology, Dana–Farber Cancer Institute, Boston, MA 02115 Dana-Farber Cancer Institute, Boston, MA From the Divisions of Hematologic Malignancies and Biostatistics, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA. 2LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Harvard Medical School Boston MA USA; Jerome Lipper Multiple Myeloma Center Division of Hematologic Malignancy, Dana–Farber Cancer Institute Boston MA USA From the Department of Adult Oncology, Dana-Farber Cancer Institute, and the Department of Medicine, Harvard Medical School, Boston, MA; and the Department of Hematology, Singapore General Hospital, Singapore. 12Dana-Farber Cancer Institute, Boston, Massachusetts. From the Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA; and Office of Oncology Drug Products and Division of Oncology Drug Products, US Food and Drug Administration, Rockville, MD From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA. Jerome Lipper Center for Multiple Myeloma Research Dana‐Farber Cancer Institute Boston Massachusetts USA 2Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Dana-Farber/Partners CancerCare Dana-Farber Cancer Institute, USA. Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Division of Hematologic Malignancy, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA From the Department of Adult Oncology and Biostatistics, Dana-Farber Cancer Institute, the Department of Radiation Therapy, Brigham and Women’s Hospital, and the Departments of Medicine and Radiation Oncology, Harvard Medical School, Boston, MA. From the Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA; and the Department of Haematology, Singapore General Hospital, Singapore. 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts; and Kraft Family Blood Donor Center, Harvard Medical School, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 1Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Callisto Pharmaceuticals Inc, New York, NY. Department of Medical Oncology The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center Dana‐Farber Cancer Institute Harvard Medical School Boston MA USA Harvard Medical School Boston Massachusetts; Dana‐Farber Cancer Institute Boston Massachusetts From the Jerome Lipper Multiple Myeloma Center Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the Institut National de la Santé et de la Recherche Médicale (INSERM) U0601, Institut de biologie and Service d'hématologie clinique, Hôtel-Dieu Centre Hospitalier Universitaire (CHU) de Nantes, Nantes, France. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; *Department of Medical Oncology, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; 2LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute; and; 3Harvard Medical School, Boston, Massachusetts From the Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan; Center for Hematologic Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA; and SRL, Inc, Tokyo, Japan. Division of Hematologic Neoplasia, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02215, USA The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; From the Divisions of Hematologic Malignancies and Neoplastic Disease Mechanisms, Dana-Farber Cancer Institute and the Department of Medicine, Harvard Medical School, Boston, MA; and the Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA. 2Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston Massachusetts; The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Harvard Medical School, Boston, Massachusetts. From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, and the Department of Medicine, Harvard Medical School, Boston, MA; the Celgene Corporation, Warren, NJ; and the University of Leeds, United Kingdom. From the Academic Unit of Haematology and Oncology, University of Leeds, United Kingdom; Department of Biostatistics, Harvard School of Public Health, Boston; Department of Cancer Biology and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA. Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 5Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center Department of Medical Oncology Dana‐Farber Cancer Institute Harvard Medical School Boston MA 02115 USA From the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; the Department of Medicine, Harvard Medical School, Boston, MA; and Novartis Institutes for Biomedical Research, Oncology Research, East Hanover, NJ. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. 11Dana-Farber Cancer Institute, Boston, Massachusetts. 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; 2Harvard Medical School, Boston, Massachusetts.; 6Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA From the Veterans Administration (VA) Boston Healthcare System and the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and the University of “Magna Græcia” and Cancer Center, Catanzaro, Italy. From the Departments of Adult Oncology, Radiation Oncology, and Biostatistics, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, MA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA From the Division of Hematologic Malignancies, Dana-Farber Cancer Institute and the Department of Medicine, Harvard Medical School, Boston, MA; and the Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan. Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. kenneth_anderson@dfci.harvard.edu. Dana‐Farber Cancer Institute Boston; Harvard Medical School Boston Hematology Department, Dana-Farber Cancer Institute, Boston, MA; 8Dana-Farber/Partners Cancer Care Institute, Boston, Massachusetts. Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, From the University of Athens School of Medicine, Athens, Greece; Roswell Park Cancer Institute, Buffalo; St Vincents Catholic Medical Center; Weill Medical College of Cornell University; Adult Bone Marrow Transplantation Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN; Wilhelminenspital, Vienna, Austria; Service d'Immuno-Hématologie, Hopital Saint-Louis, Paris, France; Hospital Clinic, Barcelona; the University Hospital of Salamanca, Salamanca, Spain; Tufts... Department of Medical Oncology The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center Harvard Medical School Dana‐Farber Cancer Institute Boston MA USA Jesús F. San Miguel and Maria-Victoria Mateos, Hospital Universitario Salamanca, Instituto de Investigación Biomédica de Salamanca; Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Cientificas, Salamanca, Spain; Rudolf Schlag, Praxisklinik Dr. Schlag, Würzburg; Martin Kropff, University of Münster, Münster, Germany; Nuriet K. Khuageva, SP Botkin Moscow City Clinical Hospital, Moscow; Olga S. Samoilova, Nizhnii Novgorod Region Clinical... Authors' Affiliation: Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Dana-Farber/Brigham and Women's Cancer Center Melissa Alsina, MD, USA. Department of Medical Oncology and; Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Dana-Farber Cancer Institute; Boston, MA USA; Harvard Medical School; Boston, MA USA The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and 7Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA Authors' Affiliations: 1Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute; 2VA Boston Healthcare System; 3Center for Advanced Orthopedic Studies, Boston, Massachusetts; 4University of “Magna Græcia,” Catanzaro, Italy; 5IDD-Biotech, Dardilly, France; and 6Vaccinex, Rochester, New York Dana-Farber Cancer Institute, Boston, Massachusetts. From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA. From the Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA; the Department of Medicine, Harvard Medical School, Boston, MA; and the Novartis Institutes for BioMedical Research, Oncology Research, Basel, Switzerland. Jerome Lipper Multiple Myeloma Center; Department of Medical Oncology; Dana-Farber Cancer Institute; Harvard Medical School; Boston, MA USA 2Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 1The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, From the Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Asahi Breweries Ltd, Tokyo, Japan; and Lovelace Respiratory Research Institute, Albuquerque, NM. From the Department of Adult Oncology, Dana-Farber Cancer Institute and the Department of Medicine, Harvard Medical School; the Department of Pathology, Brigham and Womens Hospital, and the Department of Pathology, Harvard Medical School, Boston, MA. From the Department of Adult Oncology, Dana-Farber Cancer Institute, the Department of Medicine, Harvard Medical School, and the Retina Research Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA. 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; and From the Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Millennium Pharmaceuticals; Brigham and Women's Hospital, Boston, MA; Roswell Park Cancer Institute, Buffalo; Memorial Sloan-Kettering Cancer Center, New York, NY; Winship Cancer Institute, Emory University, Atlanta, GA; and University of British Columbia, Vancouver, British Columbia, Canada. 1Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston Massachusetts. From the Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and Dana-Farber Cancer Institute, Boston, Massachusetts The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute; and Dana-Farber Cancer Institute, Boston, MA; From the Division of Hematology, Mayo Clinic, Rochester, MN; and Dana-Farber Cancer Institute, Boston, MA Dana-Farber/Brigham and Women's Cancer Center. From the Dana Farber Cancer Center, Boston, MA; Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN; and Mayo Clinic College of Medicine and Mayo Foundation, Scottsdale, AZ. Dana Farber Cancer Institute, Boston, MA; and From the Department of Adult Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, and Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA. 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute;; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts and 3The Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Dana Farber Cancer Institute Boston MA USA Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;; Harvard Medical School, Boston, MA; From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA; Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA; Aton Pharma, Tarrytown, NY; and Memorial Sloan-Kettering Cancer Center, New York, NY. From the Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA; the Division of Medical Oncology, the Massachusetts General Hospital, Boston, MA; the Department of Medicine, Harvard Medical School, Boston, MA; and the Department of Haematology, Singapore General Hospital, Singapore. 48Dana Farber Cancer Institute, Harvard School of Medicine, Harvard University, Boston, Massachusetts. 6Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Dana‐Farber Cancer Institute, Boston, Massachusetts, USA 1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; and From the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; the VA Boston Healthcare System, Harvard Medical School, Boston, MA; the University of “Magna Græcia,” Catanzaro, Italy; ImmunoGen, Cambridge, MA; and Diaclone Research, Besançon cedex, France. St. Vincent's Comprehensive Cancer Center, New York, New York, USA. From the Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Weill Medical College of Cornell University, New York, NY; and the Genetics Branch, National Cancer Institute, Bethesda, MD. Department of Medicine, Harvard Medical School, Boston, MA;; LeBow Institute for Myeloma Therapeutics and; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts DANA-FARBER CANCER INSTITUTE 2Dana Farber Cancer Institute, Boston, Massachusetts;; 3Harvard Medical School, Boston, Massachusetts; Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215-5450, USA From the University of Arkansas for Medical Science, Little Rock, AR; Mayo Clinic, Rochester, MN; Dana-Farber Cancer Institute, Boston, MA; University Hospitals of Cleveland, Cleveland, OH; Wake Forest University School of Medicine, Winston-Salem, NC; Southwest Oncology Group Statistical Center, Seattle, WA; Wichita Community Clinical Oncology Program, Wichita, KS; Columbia River Community Clinical Oncology Program, Portland, OR; Henry Ford Hospital, Detroit, MI; St Jude Children's Research Hospital,... Dana-Farber Cancer Institute, USA. From the Department of Medical Oncology, Dana-Farber Cancer Institute, and the Department of Medicine, Harvard Medical School, Boston, MA; the VA Hospital, Boston, MA; and the Novartis Institutes for Biomedical Research, Oncology Research, East Hanover, NJ. Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber... Authors' Affiliations: 1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; 2Institute for Nutritional Sciences, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, China, and Children's Hospital, Boston, Massachusetts; and 3Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas From the Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, VA Boston Healthcare System, and Harvard Medical School, Boston, MA; Division of Hematology, Mayo Clinic, Rochester, MN; and Cyclacel Ltd, Dundee, United Kingdom. Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana–Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; Department of Medicine, Harvard Medical School, Boston, MA 02115; Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114; and Genomics Center, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, Boston, MA 02115 Department of Medical Oncology Dana‐Farber Cancer Institute Harvard Medical School Boston MA 02215 USA Harvard Medical School Boston MA USA; Dana‐Farber Cancer Institute Boston MA USA 1Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; 3LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts. |
Incoming Links
Total number of triples: 1270.